Brexit: MHRA Grilling Gives A Regulator's View Of The Stakes
This article was originally published in SRA
Executive Summary
Many of those in the life sciences sector who would be affected by a possible UK departure from the EU, including industry, scientists, the academic community and lawyers, have been happy to make their views known as to the likely effects. The voice of the drug regulators in this debate, though, has been understandably muted.
You may also be interested in...
UK Votes To Leave The EU – Where Next For The Life Sciences?
UK vote to leave the EU opens the prospect of years of negotiations over the union's future relationship with one of its most valued member states.
The Brexit Effect: What Would It Mean For Europe's Future Patent System?
UK referendum on whether to remain in EU will take place around the time that the Unified Patent Court is expected to launch.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.